Skip to content- XW01 Subcutaneous Tissue
- XW013 Percutaneous
- XW0131 Daratumumab and Hyaluronidase-fihj
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0134 Teclistamab Antineoplastic
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0139 Satralizumab-mwge
- XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013F Other New Technology Therapeutic Substance
- XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013G REGN-COV2 Monoclonal Antibody
- XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013H Other New Technology Monoclonal Antibody
- XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013K Leronlimab Monoclonal Antibody
- XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013L Elranatamab Antineoplastic
- XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013S COVID-19 Vaccine Dose 1
- XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013T COVID-19 Vaccine Dose 2
- XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013U COVID-19 Vaccine
- XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013V COVID-19 Vaccine Dose 3
- XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013W Caplacizumab
- XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW01X External
- XW01X2 Anacaulase-bcdb
- XW01X27 Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7